By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Moderna Therapeutics, Inc. 

200 Tech Square

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-714-6500 Fax: 617-583-1998


SEARCH JOBS
Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellular or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.

Our novel chemistry enables messenger RNA to elude the body’s innate immune response. Once delivered, stable messenger RNA is translated into active, native protein by cells’ natural, well-tuned machinery for protein production. To date, we have made great strides in advancing messenger RNA as a drug platform, and have screened more than 100 new chemistries. Our current formulation represents a 50-fold increase in in vivo protein expression over our first generation chemistry, even as we have exponentially reduced the cost associated with manufacturing our messenger RNA Therapeutics™. We have also developed a broad intellectual property estate including 200 patent applications with 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions.

Moderna plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients.

Based in Cambridge, Massachusetts, Moderna is privately held and was founded in 2010 by Flagship VentureLabs in association with leading scientists from Boston Children’s Hospital and Massachusetts Institute of Technology.


Key Statistics


Email: info@modernatx.com
Ownership: Private

Web Site: Moderna Therapeutics, Inc.
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Moderna Therapeutics, Inc. Appoints Oncology Leader Dr. Stephen Kelsey As President Of Onkaido Therapeutics 7/1/2014 11:39:45 AM
Moderna Therapeutics, Inc. Named To CNBC Disruptor 50 List 6/17/2014 12:44:32 PM
Booming Moderna Therapeutics, Inc. Doubles Footprint In Cambridge Due To Rapid Growth 6/12/2014 6:31:14 AM
Moderna Therapeutics, Inc. Forms Technology Advisory Board To Provide Expertise For The Company's GMP Manufacturing Strategy 5/21/2014 9:50:58 AM
Moderna Therapeutics, Inc. Appoints Biotechnology Investment Banking Veteran Lorence Kim As Chief Financial Officer 3/6/2014 6:51:02 AM
Rich With $20 Million And 15 Preclinical Candidates, Moderna Therapeutics, Inc. Spins Out MRNA Cancer Drugs Into New Company 1/15/2014 6:46:19 AM
Alexion Pharmaceuticals Inc. (ALXN), Moderna Therapeutics, Inc. Ink $100 Million Rare-Disease Pact 1/13/2014 7:22:49 AM
Moderna Therapeutics, Inc. To Present At 32nd Annual J.P. Morgan Healthcare Conference 1/6/2014 6:29:40 AM
Moderna Therapeutics, Inc. Appoints Theo Melas-Kyriazi To Board of Directors 12/17/2013 6:59:58 AM
Moderna Therapeutics Sucks Up Another $110 Million To Make Messenger RNA Drugs 11/20/2013 7:32:56 AM
12
//-->